Related Experiment Video

Updated: Aug 27, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling

Dario Diviani1, Francesco Raimondi2, Cosmo D Del Vescovo1

  • 1Department of Pharmacology and Toxicology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 27, 1005 Lausanne, Switzerland.

Cell Chemical Biology
|September 6, 2016
PubMed

Insights

Researchers discovered a new compound that inhibits the AKAP13 (Lbc) protein, a key driver of cancer cell growth and spread. This targeted approach halts oncogenic Rho signaling, offering potential new therapies for prostate cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Uncontrolled Rho signaling, particularly via AKAP13 (Lbc), is linked to aggressive cancers and treatment resistance.
  • Identifying specific molecular targets is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To identify structural determinants of Lbc-RhoA interaction.
  • To discover and characterize a small molecule inhibitor of Lbc-RhoA interaction.
  • To evaluate the therapeutic potential of inhibiting Lbc-RhoA signaling in prostate cancer cells.

Main Methods:

  • Structure prediction and alanine scanning mutagenesis of Lbc.
  • Virtual screening for Lbc-RhoA interaction inhibitors.
  • In vitro biochemical assays and cell-based assays to assess inhibitor efficacy.
  • Analysis of cancer cell phenotypes including proliferation, migration, and invasiveness.

Main Results:

  • A critical region for RhoA recognition and activation by Lbc was identified.
  • A novel small molecule inhibitor targeting the Lbc DH domain was discovered.
  • The inhibitor effectively blocked Lbc-RhoA interaction and oncogenic signaling.
  • Inhibition reversed key cancer cell phenotypes, including proliferation and invasiveness.

Conclusions:

  • This study provides structural insights into Lbc-RhoA recognition.
  • Structure-based drug discovery successfully yielded an inhibitor of oncogenic Rho signaling.
  • The findings demonstrate therapeutic potential for targeting Lbc-RhoA interactions in cancer treatment.
Keywords:
AKAP13 oncogeneRas GTPasesRhoGEFscomparative modelingvirtual screening

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K